On November 25, 2025, the label for Estradiol received a new Boxed Warning from the FDA. This significant update highlights serious risks associated with Estrogen-Alone Therapy, including endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia. The warning specifically notes an increased risk of endometrial cancer in women with a uterus who use unopposed estrogens.
Background
The FDA's decision to add a Boxed Warning to the Estradiol label reflects the agency's ongoing commitment to patient safety. Estradiol is a form of estrogen used in various therapeutic contexts. The warning serves to inform healthcare professionals and patients about the potential for serious adverse outcomes when estrogen-alone therapy is administered. This type of warning is reserved for drug products that carry significant risks that may lead to serious injury or death.
What this means
The addition of a Boxed Warning to the Estradiol label necessitates a heightened level of vigilance from prescribing clinicians. Healthcare providers must now thoroughly discuss the increased risks of endometrial cancer, particularly for women with an intact uterus receiving unopposed estrogens. Furthermore, the warning calls attention to potential risks of cardiovascular disorders, breast cancer, and probable dementia. This label revision ensures that both clinicians and patients are fully aware of these serious potential adverse events, prompting careful consideration during treatment planning, patient selection, and ongoing monitoring for individuals on estrogen-alone therapy. Informed consent and patient education are paramount to mitigate these identified risks.
Source
This information regarding the Estradiol label revision was sourced from the FDA. The update, effective November 25, 2025, is detailed in the official label information available on dailymed.nlm.nih.gov.